Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
TAK-573 in relapsed/refractory multiple myeloma
NCT04392648Phase 1Withdrawn
- Sponsor
- Teva Pharmaceutical Industries Ltd.
- Start
- Jun 2020
- Primary completion
- Nov 2023
- Modality
- Antibody Fragments, Immunomodulatory ADCs, Cytokines & Interferons
01
Overview
Phase 1, open-label trial of modakafusp alfa in multiple myeloma (MM) (6 arms), sponsored by Teva Pharmaceutical Industries Ltd. Primary endpoints: Treatment Emergent Adverse Event up to 3 years, Clinically Significant Vital Signs, Laboratory Values, ECG, and Concomitant Medications up to 3 years and 1 more. Planned start Jun 2020; status: withdrawn.
02
Drugs
modakafusp alfa
03
Conditions
multiple myeloma (MM)
Beyond the preview
Go deeper on NCT04392648.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04392648.